Ralph Weichselbaum to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Ralph Weichselbaum has written about Tumor Necrosis Factor-alpha.
Connection Strength
4.688
-
Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
Score: 0.242
-
Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010 Feb 15; 70(4):1534-43.
Score: 0.241
-
Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 2009 Aug; 16(8):609-19.
Score: 0.229
-
Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
Score: 0.221
-
Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 2008 Mar; 15(3):133-9.
Score: 0.208
-
Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB. Int J Oncol. 2007 Dec; 31(6):1519-28.
Score: 0.207
-
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res. 2007 Oct 15; 13(20):6217-23.
Score: 0.205
-
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res. 2004 Sep 15; 64(18):6381-4.
Score: 0.166
-
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004 Sep 01; 10(17):5747-53.
Score: 0.165
-
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
Score: 0.165
-
Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther. 2003 Jul-Aug; 2(4):326-9.
Score: 0.153
-
Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. Am Surg. 2003 Jan; 69(1):24-7.
Score: 0.147
-
TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther. 2002 Nov; 9(11):951-7.
Score: 0.146
-
Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov; 3(11):665-71.
Score: 0.146
-
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
Score: 0.143
-
Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int J Cancer. 2002 Feb 01; 97(4):410-5.
Score: 0.138
-
Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001; 40(6):735-8.
Score: 0.128
-
Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998 Nov-Dec; 5(6):344-9.
Score: 0.110
-
Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998 Mar; 5(3):293-300.
Score: 0.105
-
Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. Nanomedicine. 2017 07; 13(5):1833-1839.
Score: 0.099
-
Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996 Oct 01; 56(19):4311-4.
Score: 0.096
-
Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 1995 Dec 01; 55(23):5561-5.
Score: 0.090
-
Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am. 1995 Sep-Oct; 1(3):204-9.
Score: 0.089
-
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995 Aug; 1(8):786-91.
Score: 0.088
-
Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res. 1995 Mar 01; 55(5):991-4.
Score: 0.086
-
Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994 Aug 15; 54(16):4266-9.
Score: 0.082
-
Ketoconazole attenuates radiation-induction of tumor necrosis factor. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):777-80.
Score: 0.082
-
Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction. Proc Natl Acad Sci U S A. 1994 May 24; 91(11):4897-901.
Score: 0.081
-
Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
Score: 0.072
-
SOD2-mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and amifostine. Free Radic Biol Med. 2011 Nov 15; 51(10):1918-25.
Score: 0.067
-
Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res. 1991 Sep 01; 51(17):4565-9.
Score: 0.067
-
The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys. 1990 Jul; 19(1):69-74.
Score: 0.062
-
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A. 1989 Dec; 86(24):10104-7.
Score: 0.060
-
Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis. 2007; 24(7):521-31.
Score: 0.051
-
Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 2006 Jan 01; 13(1):1-6.
Score: 0.045
-
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15; 22(4):592-601.
Score: 0.040
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.035
-
Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther. 2001 Jun 10; 12(9):1109-31.
Score: 0.033
-
Radiation-inducible gene therapy. C R Acad Sci III. 1999 Feb-Mar; 322(2-3):225-8.
Score: 0.028
-
Increased injection number enhances adenoviral genetic radiotherapy. Radiat Oncol Investig. 1997; 5(5):220-6.
Score: 0.024
-
Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J Clin Invest. 1991 May; 87(5):1794-7.
Score: 0.016
-
Control of gene therapy by MDR1 and EGR1 promoter sequences in transcriptional targeting by chemotherapy (Review). Int J Oncol. 2004 Mar; 24(3):731-6.
Score: 0.010
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.009
-
Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Mol Cell Biol. 1999 Apr; 19(4):2986-97.
Score: 0.007